1. ALLA AKTIER
  2. NYHETER
  3. PROLIGHT DIAGNOSTICS

Prolight Diagnostics

Nyheter Prolight Diagnostics Nyheter alla bolag

Prolight Diagnostics publishes investorletter for January 2026

The investor letter outlines that Prolight has continued to make important progress in the development of the Psyros platform. Progress in cartridge manufacturing scale-up, alongside continued refinement of the instrument design, further strengthens the platform as the company prepares for the commercial launch. 

The investor letter is available via the attached file or on the company’s website:https://prolightdx.com/en/mediaeng/investor-letters/

For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Prolight Diagnostics - Investor Letter January 2026
Prolight Diagnostics publishes investorletter for January 2026

Datum 2026-01-28, kl 11:55
Källa MFN
Bifogade filer
Prolight Diagnostics - Investor Letter January 2026
Prolight Diagnostics publishes investorletter for January 2026
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!